QIAGEN Company Receives Innovation & Leadership of the Year Award
Frost and Sullivan recognizes Genaco's Collaboration with Luminex Corporation in the Molecular Diagnostics Market
VENLO, The Netherlands, February 26, 2007 - QIAGEN, the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today announced that its wholly owned subsidiary Genaco Biomedical Products, Inc., and Luminex Corporation received the 2006 Technology Innovation and Leadership Award from Frost and Sullivan. This award was announced on February 21 at the annual Excellence in Healthcare Awards in London. This award is bestowed annually to the company or collaboration demonstrating excellence in innovation. Frost and Sullivan recognized that Genaco and Luminex brought together two proprietary technologies to develop a unique solution for multiplex polymerase chain reaction (PCR) assays used in infectious disease testing.
With its proprietary QIAplex technology, Genaco has developed a line of innovative research products. QIAplex provides rapid results in infectious disease by amplifying 20 different mutants simultaneously. Combined with Luminex's xMAP technology, which can multiplex 100 assays simultaneously within a single sample, the two companies have revolutionized infectious disease testing. QIAGEN markets the xMAP technology under the Liquichip brand.
"We are very pleased that a new member of the QIAGEN Group has received this award," said Peer Schatz, Chief Executive Officer of QIAGEN. "Genaco's innovative solutions leverage QIAGEN sample and assay technologies and offer novel and highly attractive molecular diagnostics solutions to our customers in research, in life sciences, applied testing and molecular diagnostics. The acquisition of Genaco in October 2006 allowed us to further execute our strategy of expanding our market and technology leadership in molecular diagnostics. Dennis Grimaud, the former CEO, Jian Han, the Company's founder and the entire team at Genaco have developed a technology platform that holds exciting potential in this increasingly important market segment."
Genaco's innovative mulitiplexing technology is suitable for use on a wide array of detection instruments. It was optimized and marketed for use on the Luminex detection system which QIAGEN has also been selling since 2000. Through the acquisition, QIAGEN became uniquely positioned to provide an automated, complete molecular diagnostics multiplexing solution to its research, applied testing and diagnostic customers.
Multiplexed molecular tests are widely adopted in genetic or in HLA (Human Leukocyte Antigen) testing i.e. to determine whether transplant donors and recipients are compatible. They make up a rapidly growing segment in the expanding market of molecular diagnostics, which provides modern medicine with tools for developing completely new strategies in the battle against diseases. Genaco's multiplexing tests are synergistic with QIAGEN's portfolio of molecular diagnostic assays, which in the segment of infectious disease diagnostics is considered to be the broadest in the world. QIAGEN offers more molecular diagnostic reagents and testing solutions than any other company. These products are not available for clinical use in the United States. QIAGEN develops integrated solutions for, and together with, 15 manufacturers from the pharmaceutical and diagnostics industries.
QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions for research in life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 1,900 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN is using the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. Current QIAGEN molecular diagnostics products are 34 EU CE IVD assays, three EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents. Further information about QIAGEN can be found at www.qiagen.com.
Dr. Thomas Theuringer
Nicole A. York